Could janus kinase (JAK) inhibitors like Eli Lilly's rheumatoid arthritis drug Olumiant be repurposed to treat Alzheimer's disease? Researchers at Harvard University and Massachusetts General Hospital have set out to find the answer to that question with a new clinical trial that was born from artificial intelligence. The researchers used a type of AI called machine learning to identify existing drugs that might be able to prevent neuronal death in Alzheimer's. The screen pulled up a list of 15 FDA-approved drugs as candidates for repurposing in Alzheimer's, and five of them were JAK inhibitors, they reported in the journal Nature Communications. JAK proteins fuel inflammation and have long been suspected to play a role in Alzheimer's.
Mar-9-2021, 21:31:20 GMT